Who to call at Esteve, and when
Fundz watches for the moments Esteve starts buying, and tells you who to reach.
- An alert the day Esteve raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Esteve, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Esteve. With Fundz connected, it knows.
ESTEVE signs a licensing agreement for Increlex® treatment of severe primary insulin-like growth factor 1 deficiency
Contract Type
agreement
BarcelonaManufacturingBiotechnologyHealth CarePharmaceuticalDescription
ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals for Increlex® with global rights, except for USA. Increlex® is a biologic product used for the long-term treatment of growth failure in patients aged 2 to 18 years due to severe primary insulin-like-growth-factor-1 deficiency (SPIGFD). The medication is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is designated as an 'orphan medicine' for rare diseases.
Related People
Esteve signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.